Patents by Inventor John Manfredi

John Manfredi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6911311
    Abstract: An in vitro method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in a substantially cell free environment. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: June 28, 2005
    Assignee: Myriad Genetics, Inc.
    Inventor: John Manfredi
  • Publication number: 20050137213
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 6, 2004
    Publication date: June 23, 2005
    Applicant: Myriad Genetics, Incorporated
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Publication number: 20050065064
    Abstract: The chemokine receptor CXCR4 is a co-receptor for T-tropic strains of HIV-1. A number of small molecule antagonists of CXCR4 are in development, but all are likely to lead to adverse effects due to the physiological function of CXCR4. To prevent these complications, allosteric agonists may be therapeutically useful as adjuvant therapy in combination with small molecule antagonists. A synthetic cDNA library coding for 160,000 different SDF-based peptides was screened for CXCR4 agonist activity in a yeast strain expressing functional receptor. Peptides that activated CXCR4 in an autocrine manner induced colony formation. Two peptides, designated RSVM and ASLW, were identified as novel agonists that are insensitive to the CXCR4 antagonist AMD3100. In chemotaxis assays using the acute lymphoblastic leukemia cell line CCRF-CEM, RSVM behaves as a partial agonist and ASLW as a superagonist. The superagonist activity of ASLW may be related to its inability to induce receptor internalization.
    Type: Application
    Filed: August 8, 2003
    Publication date: March 24, 2005
    Inventors: Elias Lolis, Aristidis Sachpatzidis, Henrik Dohlman, John Manfredi
  • Publication number: 20050059135
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Application
    Filed: January 5, 2004
    Publication date: March 17, 2005
    Inventors: Christine Klein, Andrew Murphy, Dana Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Patent number: 6828112
    Abstract: A method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: December 7, 2004
    Assignee: Myriad Genetics, Inc.
    Inventors: John Manfredi, Jay Zhang
  • Publication number: 20040197840
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of &agr;-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Application
    Filed: June 18, 2003
    Publication date: October 7, 2004
    Applicant: Cadus Technologies, Inc.
    Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
  • Publication number: 20030108999
    Abstract: The invention provides recombinant cells that have been engineered such that ligand stimulation of a receptor expressed by the cells leads to amplified signal transduction responses. In one embodiment, the receptor-expressing cells have been engineered to carry a heterologous DNA construct comprising a gene encoding a protein that activates the signal transduction pathway, which gene is operatively linked to a promoter that is responsive to activation of the signal transduction pathway. Stimulation of the receptor by a ligand leads to expression of the heterologous DNA construct encoding the protein that activates the signal transduction pathway such that signals generated by ligand binding to the receptor are amplified. Preferred cells are yeast cells expressing heterologous G protein coupled receptors functionally coupled to the yeast pheromone response pathway and overexpressing Ste5p, Ste4p, Ste12p, Ste11p or a dominant truncation allele of Ste20 via a pheromone-responsive promoter.
    Type: Application
    Filed: October 8, 2002
    Publication date: June 12, 2003
    Applicant: CADUS TECHNOLOGIES, INC.
    Inventors: John Manfredi, Benjamin K. Benton, Meng-Yu Wu
  • Patent number: 6562576
    Abstract: A method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in yeast cells. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: May 13, 2003
    Assignee: Myriad Genetics, Inc.
    Inventor: John Manfredi
  • Patent number: 6551786
    Abstract: A method for selecting compounds capable of modulating protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in the presence of test compounds. The interaction between the two fusion proteins leads to protein trans-splicing, producing an active reporter. Compounds that disrupt or enhance protein-protein interactions can be selected based on the presence or absence of the active reporter.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: April 22, 2003
    Assignee: Myriad Genetics, Inc.
    Inventor: John Manfredi
  • Publication number: 20030054402
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Application
    Filed: September 13, 2001
    Publication date: March 20, 2003
    Applicant: Cadus Pharmaceutical Corporation
    Inventors: Christine A. Klein, Andrew J.M. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Publication number: 20030008380
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of &agr;-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Application
    Filed: May 10, 1999
    Publication date: January 9, 2003
    Inventors: DANA MERRIMAN FOWLKES, JIM BROACH, JOHN MANFREDI, CHRISTINE KLEIN, ANDREW J. MURPHY, DR. JEREMY PAUL, JOSHUA TRUEHEART
  • Publication number: 20020106693
    Abstract: An in vitro method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in a substantially cell free environment. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Application
    Filed: January 4, 2002
    Publication date: August 8, 2002
    Applicant: Myriad Genetics, Inc.
    Inventor: John Manfredi
  • Publication number: 20020106698
    Abstract: A method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in yeast cells. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Application
    Filed: January 4, 2002
    Publication date: August 8, 2002
    Applicant: Myriad Genetics, Incorporated
    Inventor: John Manfredi
  • Publication number: 20020106632
    Abstract: A method for selecting compounds capable of modulating protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in the presence of test compounds. The interaction between the two fusion proteins leads to protein trans-splicing, producing an active reporter. Compounds that disrupt or enhance protein-protein interactions can be selected based on the presence or absence of the active reporter.
    Type: Application
    Filed: January 4, 2002
    Publication date: August 8, 2002
    Applicant: Myriad Genetics, Inc.
    Inventor: John Manfredi
  • Publication number: 20020106699
    Abstract: A method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Application
    Filed: January 4, 2002
    Publication date: August 8, 2002
    Inventors: John Manfredi, Jay Zhang
  • Publication number: 20010026926
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Application
    Filed: December 21, 2000
    Publication date: October 4, 2001
    Applicant: Cadus Pharmaceutical Corporation.
    Inventors: Christine A. Klein, Andrew J. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Patent number: 6255059
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a yeast expression library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: July 3, 2001
    Assignee: Cadus Pharmaceutical Corporation
    Inventors: Christine A. Klein, Andrew J. M. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Patent number: 6100042
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: August 8, 2000
    Assignee: Cadus Pharmaceutical Corporation
    Inventors: Dana Merriman Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
  • Patent number: 5876951
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 2, 1999
    Assignee: Cadus Pharmaceutical Corporation
    Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
  • Patent number: 5789184
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of .alpha.-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 4, 1998
    Assignee: Cadus Pharmaceutical Corporation
    Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart